GSK plc (LON:GSK) Insider Emma Walmsley Acquires 8 Shares

GSK plc (LON:GSKGet Free Report) insider Emma Walmsley bought 8 shares of the business’s stock in a transaction on Friday, February 9th. The stock was bought at an average price of GBX 1,662 ($20.99) per share, with a total value of £132.96 ($167.92).

GSK Stock Performance

Shares of LON GSK opened at GBX 1,626.40 ($20.54) on Tuesday. The stock has a market cap of £66.03 billion, a price-to-earnings ratio of 1,355.33, a P/E/G ratio of 1.29 and a beta of 0.26. The company has a current ratio of 0.88, a quick ratio of 0.73 and a debt-to-equity ratio of 140.82. GSK plc has a 1-year low of GBX 1,302.60 ($16.45) and a 1-year high of GBX 1,674.40 ($21.15). The stock’s 50-day moving average is GBX 1,523.19 and its 200 day moving average is GBX 1,464.01.

GSK Increases Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, April 11th. Investors of record on Thursday, February 22nd will be issued a dividend of GBX 16 ($0.20) per share. This represents a dividend yield of 1.04%. This is a boost from GSK’s previous dividend of $14.00. The ex-dividend date of this dividend is Thursday, February 22nd. GSK’s dividend payout ratio (DPR) is currently 5,333.33%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on GSK shares. Shore Capital restated a “buy” rating on shares of GSK in a research note on Wednesday, January 31st. Berenberg Bank reiterated a “buy” rating and set a GBX 1,650 ($20.84) price target on shares of GSK in a research report on Friday, November 24th. Citigroup reiterated a “neutral” rating on shares of GSK in a research report on Tuesday, November 28th. Finally, Barclays reiterated a “buy” rating and set a GBX 1,950 ($24.63) price target on shares of GSK in a research report on Friday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of GBX 1,650 ($20.84).

Check Out Our Latest Analysis on GSK

GSK Company Profile

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Further Reading

Insider Buying and Selling by Quarter for GSK (LON:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.